Back to search

Article

A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-H

2025-05-05

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold> Patients with POLE/POLD1 gene mutation and dMMR/MSI-H are the dominant groups with immune benefit and may benefit from immunotherapy. At present all guidelines recommend observation or chemotherapy based on stage and risk factors for postoperative adjuvant treatment of gastric adenocarcinoma or colorectal cancer. There is no definitive conclusion as to whether...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5a346f3b-830a-5765-8525-e021cf2d0c2a
DOI
10.21203/rs.3.rs-6291620/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-HDOI 10.21203/rs.3.rs-6291620/v1
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)Semantic proximity
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONOSemantic proximity
Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studySemantic proximity
Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinomaSemantic proximity
[Interpretation on 2013 updated Chinese Consensus on the Diagnosis and Treatment of Gastrointestinal Stromal Tumors].Semantic proximity
The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancerSemantic proximity
Accelerated clinical response achieved by combining short-term tumor-directed photodynamic therapy with immunotherapy-based systemic therapies in synchronous colorectal cancer with MSI-H and POLE mutation: a case report.Semantic proximity
[Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].Semantic proximity
Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety AssessmentSemantic proximity
[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].Semantic proximity
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.Semantic proximity
Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in ChinaSemantic proximity
Select a neighboring publication to make it the new centre.